



# Chronic Subdural Haematoma in the Elderly: Is It Time for a New Paradigm in Management?

J. Shapey<sup>1</sup> · L. J. Glancz<sup>2</sup> · P. M. Brennan<sup>3</sup>

Published online: 23 March 2016

© The Author(s) 2016. This article is published with open access at [Springerlink.com](http://Springerlink.com)

**Abstract** Chronic subdural haematoma (CSDH) is a common neurological condition that usually affects the elderly. The optimal treatment strategy remains uncertain, principally because there is a lack of a good evidence base. In this paper, we review the literature concerning the peri-operative and operative care of patients. In particular, we highlight the non-surgical aspects of care that might impact on patient outcomes and CSDH recurrence. We propose that an integrated approach to care in patients with CSDH, similar to care of fragility fractures in the elderly, may be an important strategy to improve patient care and outcomes.

**Keywords** Chronic subdural haematoma · CSDH · Elderly · Peri-operative care · Outcomes

## Introduction

The incidence of chronic subdural haematoma (CSDH) increases with age, and after 70 years of age is 8.2/100,000/year [1]. As the population ages, the prevalence is anticipated to increase [1, 2]. CSDH is an important cause of morbidity and mortality and it has been described as a ‘sentinel health event’ indicating underlying systemic pathology. CSDH has a 1-year mortality similar to that of hip fractures [2].

It is surprising then that little class I evidence exists to describe the optimal surgical and peri-operative management of CSDH. This is important, because improving outcomes in this elderly and often frail population requires us to make informed decisions at all stages of their management, not just in the operating theatre. We need to understand the impact of both surgical and non-surgical treatment decisions on patient outcomes and CSDH recurrence.

The peer-reviewed literature actually offers often conflicting advice regarding CSDH management, leading to considerable variation in practice. For example, the most common surgical strategy for evacuation of a CSDH is burr hole craniotomy, but the optimal number of burr holes (one vs. two) is uncertain [3, 4]. Post-operatively, there is also contradictory advice about the relative risk of bed rest and early mobilisation on CSDH recurrence or post-operative morbidity [5–7]. Other uncertainties include the benefit of corticosteroids as either a primary treatment or an adjunct to surgery and the need to administer agents to mitigate the biological effects of antiplatelet medication pre-operatively (e.g., platelet transfusion) [8, 9]. We will review these in more detail.

Clinical uncertainties create potential risk for elderly patients. A sound evidence base is therefore urgently needed. Crucially, this should focus not only on surgical practice, but should also take into account all stages of the patient pathway from diagnosis to rehabilitation. We review the evidence base

This article is part of the Topical Collection on *Neurology of Aging*

✉ P. M. Brennan  
[paul.brennan@ed.ac.uk](mailto:paul.brennan@ed.ac.uk)

J. Shapey  
[jshapey@doctors.org.uk](mailto:jshapey@doctors.org.uk)

L. J. Glancz  
[laurenceglancz@doctors.org.uk](mailto:laurenceglancz@doctors.org.uk)

<sup>1</sup> National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

<sup>2</sup> Department of Neurosurgery, Nottingham University Hospitals NHS Trust, Nottingham, UK

<sup>3</sup> Department of Clinical Neurosciences, Western General Hospital, University of Edinburgh, Edinburgh, UK

for the peri-operative and operative care of patients with CSDH. In particular, we discuss the non-surgical interventions that might facilitate patient recovery and rehabilitation.

## Pathophysiology

CSDH is a collection of liquefied blood between the dura and arachnoid layer of the brain thought to result from injury to bridging veins crossing the subdural space. Head injury is a common risk factor and in a study of 1000 patients, 61.7 % recalled a recent one [10]. Other risk factors include coagulopathy, use of antiplatelet or anticoagulant medication, over-drainage from a cerebrospinal diversion device, haematological malignancies and vascular malformations [11••].

CSDHs often present several weeks or months after the index bleed, because as the initial acute haematoma liquefies it enlarges. This increasing volume causes mass effect that manifests clinically. Two principal theories have been proposed for the mechanism of clot enlargement. Firstly, that the liquefying clot has increased protein content exerting an osmotic effect through increased oncotic pressure. However, the osmolality of the liquefied clot is actually the same as cerebrospinal fluid and blood [12]. A second theory states that recurrent bleeding occurs from abnormal and dilated blood vessels in the capsule that forms around the haematoma. Evidence from radiolabelling studies and observation of coagulation abnormalities within the CSDH itself support this theory [13]. High concentrations of vascular endothelial growth factor (VEGF) have also been demonstrated within the subdural fluid supporting the theory that ongoing angiogenesis and hyper-permeability of capillaries contributes to haematoma expansion [13].

## Clinical Presentation

Patients with chronic subdural haematomas can present in a variety of ways, and symptom onset and progression may range from days to weeks. Elderly patients frequently present with multiple symptoms that may mimic a stroke or rapidly progressive dementia. In a study of 1000 patients with CSDH, their presenting symptoms included behavioural disturbance (28.5 %), headaches (25.1 %), and limb weakness (24.8 %); behavioural disturbance was the predominant clinical feature in elderly patients [10]. Many patients have a mild reduction in their level of consciousness (Glasgow Coma Scale [GCS] score of 13–15), but elderly patients with CSDH do not typically present in coma [14••, 15•]. Bilateral subdural haematomas may be present in up to 25 % of patients, but without causing focal neurological deficits [13, 16]. Midline shift may be minimal with bilateral CSDH, but the haematomas can still exert significant mass effect. This may

increase the risk of rapid deterioration, so consideration may be given to expedited surgical drainage in these patients.

## Management

### Surgical Management

Surgical haematoma evacuation is indicated in patients who deteriorate or do not improve. Surgery can bring a rapid clinical improvement with a favourable outcome in over 80 % of patients [1]. However, the most effective surgical technique is uncertain. The three most common techniques are twist-drill craniotomy (TDC), burr hole craniotomy (BHC) and craniotomy. TDC involves making a skull opening of <5 mm and can be performed at the bedside. BHC and craniotomy are performed in the operating theatre; the former involves making one or two holes <30 mm in diameter in the skull, whereas craniotomy is generally defined as creating a >30-mm diameter bony defect which is replaced at the end of the procedure. Several studies including a recent large prospective multi-centre audit of CSDH management in the UK found BHC to be the most frequently used method of surgical drainage [17••, 18•].

### Comparison of Operational Techniques

Most studies comparing surgical techniques have been small, single-centred and retrospective. Weigel and colleagues performed meta-analyses of the available data. They reported that whilst all three techniques have approximately the same mortality (2–4 %), craniotomy has significantly higher morbidity and TDC has a higher rate of recurrence, suggesting BHC is the preferred technique [19]. A Monte Carlo decision analysis by Lega et al. also favoured BHC over TDC or craniotomy, given its low recurrence and complication rate [20]. Ducruet et al. concluded that TDC should be the first-line treatment for patients who are high-risk surgical candidates with non-septated CSDH, whilst craniotomy is reserved for patients with membranous CSDH or symptomatic recurrence. Ducruet did not specifically compare TDC to BHC, but a more recent meta-analysis by Almenawer et al. found no significant differences between TDC and BHC in mortality, morbidity or recurrence rates [18•]. However, there was a trend towards lower complication rates in patients treated with TDC [18•].

### Number of Burr Holes

Current evidence then suggests that TDC or BHC should be first-line treatment in the majority of patients with CSDH. The number of burr holes used depends on individual surgeon preference. A meta-analysis of 631 patients failed to

demonstrate a significant difference in recurrence rates related to the number of burr holes used, so single BHC appears as good as double BHC [21]. Similarly, a recent large UK audit did not demonstrate number of burr holes as an independent risk factor for CSDH recurrence [17•]. Perhaps the default surgical method should be a single burr hole, reducing operating time and potentially morbidity. Crucially, this may also permit the procedure to be performed under local anaesthetic, an attractive option in patients with cardio-respiratory morbidity. This hypothesis needs to be formally tested.

### *Irrigation*

During surgical evacuation of a CSDH, opening of the dura to release the haematoma often reveals that the collection was under tension. This release of pressure may be sufficient to improve the patient's clinical state and the role of additional intra-operative irrigation remains unclear. One study of 247 patients demonstrated a significant reduction in recurrence rates when more than 1500 ml of irrigation fluid is used [22]. However, a recent meta-analysis demonstrated no clear evidence of improvement in outcomes [18•].

### *Use of Post-operative Drains*

The most evidence-based adjunct to surgical haematoma evacuation is placement of a post-operative drain. A randomised controlled trial (RCT) demonstrated that subdural drains left in situ after BHC reduced CSDH recurrence requiring re-drainage (9.3 vs. 24.0 % recurrence with/without drain) [14•]. The benefit of drains was confirmed by three recent meta-analyses, and the placement of closed-system drainage is now standard practice [18•, 23, 24]. Some surgeons prefer placement of a less-invasive subperiosteal drain and it has been recommended that subperiosteal drains are placed in patients over 80 years of age or in those with predicable high risk for complications [25]. A direct comparison between subdural and subperiosteal drain placement has yet to be made.

### **Non-surgical Management**

In patients with mild symptoms such as minor headache, or in patients deemed unfit for surgery, there may be a role for 'watchful waiting'. Serial cranial imaging may provide information to support decision-making, but the success or otherwise of this strategy should be guided by clinical assessment. As yet, there are no evidence-based guidelines on the frequency of serial imaging.

### *Corticosteroids*

Some surgeons recommend a course of corticosteroids. Since spontaneous resolution of CSDH can occur, it is difficult to

know whether corticosteroids speed up this process. Spontaneous resolution is thought to occur when the vascular membrane around the haematoma matures, bringing an end to the recurrent small bleeding that increases or maintains the size of the haematoma. Corticosteroids may facilitate this process by down-regulating the inflammatory reaction that is thought to maintain the vascularised haematoma membrane [26]. The hypothesis that corticosteroids negate the need for surgery in some symptomatic patients and reduce the rate of recurrence in other surgically treated patients is principally derived from non-randomised studies [8, 25]. However, two prospective RCTs currently recruiting aim to definitively clarify the role of corticosteroids. Dex-CSDH is a multi-centre randomised, double blind, placebo-controlled trial of a 2-week course of tapering dexamethasone for adults with symptomatic CSDH (ISRCTN 80782810). This will assess the clinical status of the patients 6 months post-randomisation through objective disability scales, whilst also establishing progression to surgical intervention and recurrence rates in each group. The Dresh study is a double blind, placebo-controlled RCT [27]. It differs from Dex-CSDH in that the medication is prescribed post-operatively for 6 days. The end point is reoperation rates at 12 weeks.

### *Angiotensin Converting Enzyme Inhibitors*

It has been hypothesised that the concurrent treatment of hypertension with angiotensin converting enzyme (ACE) inhibitors in patients with CSDH might lower the risk of recurrence after surgery. ACEI might also lower the risk of developing CSDH through their antiangiogenic mechanism [28]. A trial to assess whether treatment with an ACE inhibitor for 3 months after surgical evacuation of CSDH will decrease the risk of recurrence is ongoing (NCT00915928).

### **Peri-operative Care of Elderly Patients with CSDH**

The 2001 National Service Framework (NSF) for older people recognised that care of the elderly patient in hospital is complex [29]. It recommends that older people be given early supervision and advice from a specialist team on hospital admission. The increased risk of peri-operative complications with advancing age in part reflects a higher incidence of coexisting disease and polypharmacy.

### *Anticoagulation and Antiplatelet Therapy*

In a recent national UK audit of CSDH management, 43 % of patients were admitted on an anticoagulant or antiplatelet medication, similar to previously published figures [30]. Anticoagulant and antiplatelet use are both implicated in CSDH development and recurrence [31]. Warfarin may increase the risk of CSDH development up to 42.5 times [30].

The increased risk from aspirin appears less [30]. The relative risk of developing a CSDH whilst taking newer antiplatelet medications has not yet been studied. The correct peri-operative management of anticoagulant and antiplatelet medication is therefore extremely important.

#### *Anticoagulant Medication*

The required speed of reversal of anticoagulant and antiplatelet effects to minimise intra- and post-operative bleeding complications will partly depend on the clinical urgency of surgery. Vitamin K usually provides a more gradual normalisation of the international normalised ratio (INR), but may be used in conjunction with fresh frozen plasma (FFP), prothrombin complex concentrate (PCC) or recombinant factor VIIa (rfVIIa) to speed up reversal and avoid INR rebound [32]. FFP can promote fluid overload in elderly patients and may precipitate cardiac or renal impairment, so PCC may be preferred as an adjuvant to vitamin K [32, 33].

Resumption of anticoagulation therapy following surgery should be done cautiously, but the risk of recurrent haemorrhage must be weighed against increased risk of thromboembolic complications with prolonged discontinuation of anticoagulation. There is little good quality evidence in this area. There is a suggestion that oral anticoagulation may be recommended 3 days after surgery in patients with a high thromboembolic risk (e.g., patients with mechanical heart valves) [34]. The CHA<sub>2</sub>DS<sub>2</sub>-VASc thromboembolism risk score and the HAS-BLED bleeding risk score may help inform the timing in patients with atrial fibrillation [35].

#### *Antiplatelet Medication*

The effects of aspirin last until there is a 20 % new circulating platelet mass, which usually occurs 5 days after cessation of medication [36]. Clopidogrel produces abnormal bleeding for approximately the same duration after discontinuation [37]. Anecdotally, in patients with minor symptoms, surgery is therefore usually delayed for 7–10 days. However, the only study to directly examine the effects of delaying surgery on the recurrence rates of CSDH found surgery had to be delayed for only 3 days after stopping antiplatelet medications to reduce risk of recurrence [38]. Reducing the length of time patients wait for surgery may reduce other peri-operative morbidity. For emergency surgery, the American Society of Haematology recommends that patients previously taking aspirin or clopidogrel should be given a pre-operative platelet transfusion [39]. However, these recommendations do not pertain specifically to CSDH and there is no direct evidence that platelet transfusion positively influences outcomes for patients with CSDH.

Newer antiplatelet agents include a direct thrombin inhibitor (Dabigatran), an indirect Factor Xa inhibitor (Fondaparinux),

and direct Factor Xa inhibitors (Rivaroxaban and Apixaban). Factor VIII Inhibitor Bypassing Activity (FEIBA) should be the first-line reversal agent in patients taking dabigatran [37]. PCC should be first-line in patients taking rivaroxaban and rfVIIa for those on fondaparinux [37]. The effect of these antiplatelet and reversal agents on incidence of CSDH and outcomes from surgery is not yet known.

There is no quality evidence to guide the optimal timing of post-operative resumption of antiplatelet therapy in patients treated surgically for CSDH. Further prospective studies are needed to provide evidence-based recommendations.

#### *Choice of Anaesthesia*

A small number of studies have examined the influence of local (LA) and general anaesthesia (GA) on surgical CSDH evacuation. A retrospective study of patients over 60 years old undergoing BHC for CSDH demonstrated that cardiac complications were significantly higher in the GA group, who consequently had significantly longer hospital stays [40]. However, in another single-centre retrospective series of 1000 surgically treated patients, there was no significant difference in outcome between ‘monitored anaesthesia’ (LA with conscious sedation) and GA, although only 10 % of patients in this study actually underwent GA [10].

Comparisons of GA and regional/local anaesthesia have been made in non-neurosurgical practice. For example, a review of 18,715 geriatric patients undergoing hip fracture surgery concluded that spinal anaesthesia is associated with significantly reduced early mortality and a decreased risk of venous thromboembolism, delirium, myocardial infarction, pneumonia and post-operative hypoxia [41]. However, the GALA trial (general anaesthesia versus local anaesthesia for carotid surgery) failed to demonstrate a difference in outcomes (stroke, myocardial infarction or death at 30 days) between GA and LA in patients undergoing carotid surgery [42]. Interestingly, data from patients in the UK national audit of CSDH suggests that many have similar baseline characteristics to those included in the GALA trial. For now, the anaesthetist and surgeon, in consultation with the patient, must decide which anaesthetic technique to use on an individual basis. In the future, if it can be demonstrated that a single TDC or BHC with subdural drain is as effective as more extensive procedures, then the tolerability and acceptability of LA may increase.

#### *Time to Surgery*

‘Elective & Emergency Surgery in the Elderly: An Age Old Problem’, published in 2010 by the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) highlighted the increased risk of peri-operative morbidity and mortality in the elderly (<http://www.ncepod.org.uk/2010eese.htm>). The report demonstrated that delays in surgery are associated with



poorer outcome and recommends that senior clinicians in surgery, anaesthesia and medicine need to be involved in the decision to operate on elderly patients. Integrated patient care pathways can consolidate the involvement of these specialities to optimise care. For example, these pathways are now the standard of care for NHS patients presenting with a fractured neck of femur and have been shown to reduce morbidity and mortality as well as hospital length of stay [43]. The British Orthopaedic Association and the British Geriatrics Society also provide best practice guidelines in their ‘Blue Book’ publication [44]. Together with a Web-based National Hip Fracture Database (NHFD), this permits trauma units to benchmark and improve their management of this patient population.

No such guidelines or resources exist for elderly patients with CSDH and there is currently no evidence to guide best practice on timing of surgery. Instinctively, the shorter the duration of a neurological deficit, the quicker will a patient’s recovery be and the more likely the deficit is to fully recover. The relative merits of early surgery need to be weighed against the benefits of optimising the patient’s medical state for anaesthesia. A multi-disciplinary integrated patient care pathway to facilitate this is currently under development by The National Hospital, London.

#### *Post-operative Mobilisation*

Early post-operative mobilisation of patients remains a controversial issue. It is thought to reduce incidence of complications such as pneumonia and deep vein thromboses. Conversely, bed rest has been proposed to reduce recurrence by promoting brain re-expansion. A recent audit of UK practice found that 61 % of practitioners continue to prescribe bed rest for a median of 12–24 h post-operatively, but the same study also demonstrated that bed rest did not significantly affect the rate of CSDH recurrence. In fact, bed rest predicted poor outcomes (mRS 4–6) [17••]. Two prospective randomised studies have also concluded that recurrence rates after BHC are independent of patient’s post-operative position, but another demonstrated a statistically higher recurrence rate in patients mobilised immediately after surgery [5–7]. Reported complication rates as a result of early mobilisation also vary between these studies. Intuitively, if early mobilisation does not impact CSDH recurrence, then it should be beneficial to patient recovery.

### **Conclusion: Time for a New Paradigm in CSDH Management—an Evidence-Based Integrated Care Pathway**

We have demonstrated that many uncertainties remain as how to best optimise operative and peri-operative care for elderly patients with CSDH. Parallels to patients with fragility

fractures would suggest that we need an integrated, multi-disciplinary approach, minimising delay to surgery, simplifying the surgical approach and promoting early rehabilitation. A better coordination of multi-disciplinary care should also improve patient satisfaction in their treatment. Further work to establish the standards to be included in an integrated care pathway will need to address several important questions, amongst them: Is there a benefit from early transfer to a neurosurgical unit or from early surgery? Does routine access to acute medical support on admission improve peri-operative care? Is single burr hole drainage and insertion of a subdural drain performed under monitored anaesthesia (local anaesthetic with sedation) non-inferior/superior to multiple burr holes performed under general anaesthetic? Is there an adjunctive role for corticosteroids? Does early post-operative mobilisation improve long term outcomes or increase CSDH recurrence? Addressing these questions requires a coordinated approach and we invite collaboration in our future work as we endeavour to establish best practice for this vulnerable patient population.

#### **Compliance with Ethical Standards**

**Conflict of Interest** Jonathan Shapey, Paul Brennan and Laurence Glancz declare that they have no conflict of interest.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

### **References**

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Foelholm R, Waltimo O. Epidemiology of chronic subdural haematoma. *Acta Neurochir*. 1975;32:247–50.
2. Adhiyaman V, Asghar M, Ganeshram KN, Bhowmick BK. Chronic subdural haematoma in the elderly. *Postgrad Med J*. 2002;78(916): 71–5.
3. Kansal R, Nadkarni T, Goel A. Single versus double burr hole drainage of chronic subdural hematomas. A study of 267 cases. *J Clin Neurosci*. 2010;17(4):428–9.
4. Taussky P, Fandino J, Landolt H. Number of burr holes as independent predictor of postoperative recurrence in chronic subdural haematoma. *Br J Neurosurg*. 2008;22(2):279–82.

5. Abouzari M, Rashidi A, Rezaii J, Esfandiari K, Asadollahi M, Aleali H, et al. The role of postoperative patient posture in the recurrence of traumatic chronic subdural hematoma after burr-hole surgery. *Neurosurgery*. 2007;61(4):794–7.
6. Nakajima H, Yasui T, Nishikawa M, Kishi H, Kan M. The role of postoperative patient posture in the recurrence of chronic subdural hematoma: a prospective randomized trial. *Surg Neurol*. 2002;58(6):385–7.
7. Kurabe S, Ozawa T, Watanabe T, Aiba T. Efficacy and safety of postoperative early mobilization for chronic subdural hematoma in elderly patients. *Acta Neurochir (Wien)*. 2010;152(7):1171–4.
8. Berghauer Pont LME, Dirven CMF, Dippel DWJ, Verweij BH, Dammers R. The role of corticosteroids in the management of chronic subdural hematoma: a systematic review. *Eur J Neurol [Internet]*. 2012;19(11):1397–403. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22642223>
9. Zarkou S, Aguilar MI, Patel NP, Wellik KE, Wingerchuk DM, Demaerschalk BM. The role of corticosteroids in the management of chronic subdural hematomas: a critically appraised topic. *Neurologist*. 2009;15(5):299–302.
10. Gelabert-González M, Iglesias-Pais M, García-Allut A, Martínez-Rumbo R. Chronic subdural haematoma: surgical treatment and outcome in 1000 cases. *Clin Neurol Neurosurg*. 2005;107(3):223–9.
11. •• Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. *Nat Rev Neurol [Internet]*. 2014;10(10):570–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25224156> **This is a comprehensive review of CSDH from a Unit with a strong CSDH research portfolio.**
12. Weir B. The osmolality of subdural haematoma fluid. *J Neurosurg*. 1971;34(4):528–33.
13. Hohenstein A, Erber R, Schilling L, Weigel R. Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA within the neomembranes of chronic subdural hematoma. *J Neurotrauma [Internet]*. 2005;22(5):518–28. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15892598>.
14. •• Santarius T, Kirkpatrick PJ, Ganesan D, Chia HL, Jalloh I, Smielewski P, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. *Lancet*. 2009;374(9695):1067–73. **This is the RCT that has had the most impact in CSDH management and sets the standard for future studies.**
15. • Miranda LB, Braxton E, Hobbs J, Quigley MR. Chronic subdural hematoma in the elderly: not a benign disease. *J Neurosurg [Internet]*. 2011;114(1):72–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/20868215> **This is a good sized long-term retrospective follow-up in the elderly population.**
16. Huang Y-H, Yang K-Y, Lee T-C, Liao C-C. Bilateral chronic subdural hematoma: what is the clinical significance? *Int J Surg [Internet]*. 2013;11(7):544–8. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23707986>
17. •• Brennan PM, Kolias AG, Joannides AJ, Shapey J, Marcus HJ, Gregson BA, Grover PJ, Hutchinson PJ CI. The management and outcome of patients with chronic subdural haematoma: a prospective, multi-centre, observational cohort study in the United Kingdom. *Rev*. 2016. **This is the largest prospective study in CSDH every reported and defines the standard of care in the UK.**
18. • Almenawer S a, Farrokhlyar F, Hong C, Alhazzani W, Manoranjan B, Yarasavitch B, et al. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. *Ann Surg [Internet]*. 2014;259(3):449–57. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24096761> **The largest systematic review in CSDH.**
19. Weigel R, Schmiedek P, Krauss JK. Outcome of contemporary surgery for chronic subdural haematoma: evidence based review. *J Neurol Neurosurg Psychiatry*. 2003;74(7):937–43.
20. Lega BC, Danish SF, Malhotra NR, Sonnad SS, Stein SC. Choosing the best operation for chronic subdural hematoma: a decision analysis. *J Neurosurg [Internet]*. 2010;113(3):615–21. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19877806>
21. Belkhair S, Pickett G. One versus double burr holes for treating chronic subdural hematoma meta-analysis. *Can J Neurol Sci [Internet]*. 2013;40(1):56–60. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23250128>
22. Tahsim-Oglou Y, Beseoglu K, Hänggi D, Stummer W, Steiger HJ. Factors predicting recurrence of chronic subdural haematoma: the influence of intraoperative irrigation and low-molecular-weight heparin thromboprophylaxis. *Acta Neurochir (Wien)*. 2012;154(6):1063–7.
23. Liu W, Bakker N a, Groen RJM. Chronic subdural hematoma: a systematic review and meta-analysis of surgical procedures. *J Neurosurg [Internet]*. 2014;121(1):1–9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24995782>
24. Alcalá-Cerra G, Young AMH, Moscote-Salazar LR, Paternina-Cañedo Á. Efficacy and safety of subdural drains after burr-hole evacuation of chronic subdural hematomas: systematic review and meta-analysis of randomized controlled trials. *World Neurosurg [Internet]*. 2014; Available from: <http://www.sciencedirect.com/science/article/pii/S1878875014007153>
25. Shofty B GR. Treatment options for chronic subdural hematoma. *World Neurosurg*. 2015;S1878–8750.
26. Zarkou S, Aguilar MI, Patel NP, Wellik KE, Wingerchuk DM, Demaerschalk BM. The role of corticosteroids in the management of chronic subdural hematomas: a critically appraised topic. *Neurologist [Internet]*. 2009;15(5):299–302. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19741442>
27. Emich S, Richling B, McCoy MR, Al-Schameri RA, Ling F, Sun L, et al. The efficacy of dexamethasone on reduction in the reoperation rate of chronic subdural hematoma—the DRESH study: straight-forward study protocol for a randomized controlled trial. *Trials [Internet]*. 2014 Jan [cited 2016 Feb 15];15:6. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3891985&tool=pmcentrez&rendertype=abstract>
28. Weigel R, Hohenstein A, Schlickum L, Weiss C, Schilling L. Angiotensin converting enzyme inhibition for arterial hypertension reduces the risk of recurrence in patients with chronic subdural hematoma possibly by an antiangiogenic mechanism. *Neurosurgery*. 2007;61(4):788–92.
29. Health D of. National service framework for older people 2001. 2001.
30. Rust T, Kierner N, Erasmus A. Chronic subdural haematomas and anticoagulation or anti-thrombotic therapy. *J Clin Neurosci*. 2006;13(8):823–7.
31. Bakheet MF, Pearce LA, Hart RG. Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials. *Int J Stroke [Internet]*. 2015 Jun [cited 2015 Aug 5];10(4):501–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25472690>
32. Woo CH, Patel N, Conell C, Rao VA, Faigles BS, Patel MC, et al. Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor vii, and prothrombin complex concentrate. *World Neurosurg*. 2014. p. 110–5.
33. Ducruet AF, Grobely BT, Zacharia BE, Hickman ZL, DeRosa PL, Anderson K, et al. The surgical management of chronic subdural hematoma. *Neurosurg Rev*. 2012. p. 155–69.
34. Kawamata T, Takeshita M, Kubo O, Izawa M, Kagawa M, Takakura K. Management of intracranial hemorrhage associated with anticoagulant therapy. *Surg Neurol [Internet]*. 1995;44(5):438–42; discussion 443. Available from: [http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&DbFrom=pubmed&Cmd=Link&LinkName=pubmed\\_pubmed&LinkReadableName=RelatedArticles&IdsFromResult=8629228&ordinalpos=3&itool=](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&DbFrom=pubmed&Cmd=Link&LinkName=pubmed_pubmed&LinkReadableName=RelatedArticles&IdsFromResult=8629228&ordinalpos=3&itool=)

- EntrezSystem2.PEntrez.Pubmed.Pubmed\_ResultsPanel.Pubmed\_RVDocSum
35. Chari A, Clemente Morgado T, Rigamonti D. Recommencement of anticoagulation in chronic subdural haematoma: a systematic review and meta-analysis. *Br J Neurosurg* [Internet]. 2014;28(1):2–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23834661>
  36. McMillian WD, Rogers FB. Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: a review. *J Trauma*. 2009;66(3):942–50.
  37. Gordon JL, Fabian TC, Lee MD, Dugdale M. Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. *J Trauma Acute Care Surg* [Internet]. 2013 Sep [cited 2016 Jan 5];75(3):475–86. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24089118>
  38. Wada M, Yamakami I, Higuchi Y, Tanaka M, Suda S, Ono J, et al. Influence of antiplatelet therapy on postoperative recurrence of chronic subdural hematoma: a multicenter retrospective study in 719 patients. *Clin Neurol Neurosurg*. 2014;120:49–54.
  39. Cushman M, Lim W ZN. Clinical practice guide on anticoagulant dosing and management of anticoagulant associated bleeding complications in adults [Internet]. 2011. Available from: <http://www.hematology.org/Practice/Guidelines/2934.aspx>
  40. Kim SO, Jung SI, Won YS, Choi CSYJ. A comparative study of local versus general anesthesia for chronic subdural hematoma in elderly patients over 60 years. *Korean. J Neurotrauma*. 2013;9(2):47–51.
  41. Luger TJ, Kammerlander C, Gosch M, Luger MF, Kammerlander-Knauer U, Roth T, et al. Neuroaxial versus general anaesthesia in geriatric patients for hip fracture surgery: does it matter? *Osteoporos Int* [Internet]. 2010 Dec [cited 2016 Feb 15];21(Suppl 4):S555–72. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/21057995>
  42. Lewis SC, Warlow CP, Bodenham AR, Colam B, Rothwell PM, Torgerson D, et al. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. *Lancet* (London, England) [Internet]. 2008;372(9656):2132–42. Available from: <http://www.sciencedirect.com/science/article/pii/S0140673608616992>
  43. Beaupre LA, Cinats JG, Senthilselvan A, Lier D, Jones CA, Scharfenberger A, et al. Reduced morbidity for elderly patients with a hip fracture after implementation of a perioperative evidence-based clinical pathway. *Qual Saf Health Care* [Internet]. 2006 Oct [cited 2016 Feb 15];15(5):375–9. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2565826&tool=pmcentrez&rendertype=abstract>
  44. Marsh D. The care of patients with fragility fracture. *British Orthopaedic Association*; 2007